


This article was downloaded by: [University of Memphis]

On: 05 July 2012, At: 07:57

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954

Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lsyc20>

### N-Hydroxyphthalimide/Cobalt Acetate, a New Catalytic Oxidative System for the Synthesis of Benzimidazoles

Gary M. Coppola<sup>a</sup>

<sup>a</sup> Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA

Version of record first published: 29 Sep 2008

To cite this article: Gary M. Coppola (2008): N-Hydroxyphthalimide/Cobalt Acetate, a New Catalytic Oxidative System for the Synthesis of Benzimidazoles, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 38:20, 3500-3507

To link to this article: <http://dx.doi.org/10.1080/00397910802162959>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan,

sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## N-Hydroxyphthalimide/Cobalt Acetate, a New Catalytic Oxidative System for the Synthesis of Benzimidazoles

Gary M. Coppola

Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA

**Abstract:** Benzimidazoles are readily prepared from 1,2-phenylenediamine and an aldehyde using air and catalytic N-hydroxyphthalimide/Co(OAc)<sub>2</sub> as the oxidant. Both electron-donating and electron-withdrawing groups are tolerated.

**Keywords:** Aerobic oxidation, aldehyde, benzimidazoles, N-hydroxyphthalimide

### INTRODUCTION


The benzimidazole heterocycle is an important structural element present in a variety of pharmacologically active molecules including the essential vitamin B-12. 2-Arylbenzimidazoles play an important role as pharmacophores in molecules exhibiting antiviral,<sup>[1]</sup> antibacterial,<sup>[2]</sup> anti-inflammatory,<sup>[2–4]</sup> antitumor,<sup>[5]</sup> anti-hypertensive,<sup>[6]</sup> and cardiogenic<sup>[7]</sup> activities.

Classical preparation of 2-arylbenzimidazoles (**5**) involves acylation of 1,2-phenylenediamine (**1**) to provide amide **2** followed by a dehydrative cyclization under thermal conditions,<sup>[8]</sup> acidic conditions (e.g., HOAc,<sup>[9]</sup> p-TosOH,<sup>[10]</sup> HCl,<sup>[11]</sup> zeolite<sup>[12]</sup>), or neutral conditions using reagents such as P<sub>2</sub>O<sub>5</sub>.<sup>[13]</sup> Another route that has gained popularity is a single-step procedure involving the condensation of **1** with an aldehyde

Received January 2, 2008.

Address correspondence to Gary M. Coppola, Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, 100 Technology Square, Cambridge, MA 02139 E-mail: gary.coppola@novartis.com

to afford Schiff base **3**, which then proceeds through the intermediacy of benzimidazoline **4**, which, in the presence of an oxidizing agent, affords the desired benzimidazole **5**. A wide variety of oxidants such as  $\text{Pb}(\text{OAc})_4$ ,<sup>[14]</sup>  $\text{FeCl}_3$ ,<sup>[15]</sup> sulfamic acid,<sup>[16]</sup>  $\text{Yb}(\text{OTf})_3$ ,<sup>[17]</sup>  $\text{Sc}(\text{OTf})_3$ ,<sup>[18]</sup> oxone,<sup>[19]</sup>  $\text{H}_2\text{O}_2/\text{HCl}$ ,<sup>[20]</sup> and  $\text{KHSO}_4$ <sup>[21]</sup> have been employed to effect the dehydrogenation step. Although many of these methods are practical, some have liabilities such as dangerous or toxic reagents, stoichiometry of the reactants, or the formation of N-benzylbenzimidazole side products resulting from further reaction of the aldehyde with **4** prior to oxidation.




The organic catalyst N-hydroxyphthalimide (NHPI) has sporadically been used in aerobic oxidations of hydrocarbons,<sup>[22]</sup> proceeding via a phthalimide N-oxy radical. Reactions are performed under an oxygen atmosphere in benzonitrile at elevated temperatures. The scope of the oxidation was broadened to include alcohols by enhancing the catalytic activity of NHPI with small quantities of  $\text{Co}(\text{acac})_n$  ( $n = 2$  or  $3$ )<sup>[23,24]</sup>; however, the process still required elevated temperature ( $100^\circ\text{C}$ ). It was later found that using  $\text{Co}(\text{OAc})_2$  as the cocatalyst allowed reactions to be performed at ambient temperature.<sup>[25]</sup> This methodology has also been applied to the oxidative aromatization of Hantzsch dihydropyridines to pyridines with similar results. In the presence of only NHPI, aromatization occurs in refluxing acetonitrile over several hours<sup>[26]</sup>; however, in the presence of both NHPI and  $\text{Co}(\text{OAc})_2$ , the reaction proceeds at ambient temperature.<sup>[27]</sup> These encouraging results prompted the investigation as to whether this catalytic system could be used in the oxidative dehydrogenation of **4** to **5**.

## RESULTS AND DISCUSSION

Because all previously reported oxidations using NHPI were conducted under an oxygen atmosphere, we wanted to ascertain whether it is imperative to use an oxygen atmosphere or if air would suffice. Gratifyingly, the reaction of **1** with 4-methoxybenzaldehyde catalyzed by 10 mol% NHPI and a minute amount of  $\text{Co}(\text{OAc})_2$  in acetonitrile in air furnished the benzimidazole in 83% yield. Because it had been reported that benzimidazoles can be formed using only air as the oxidant, albeit at elevated temperatures,<sup>[28]</sup> a parallel reaction was performed without the NHPI/ $\text{Co}(\text{OAc})_2$  catalyst, and no benzimidazole was produced.

The scope of the reaction was investigated using a variety of benzaldehydes possessing electron-donating or electron-withdrawing groups at the *ortho*, *meta* or *para* positions, and the results are listed in Table 1. Reactions using benzaldehydes containing electron-donating groups were generally complete within 6 h; however, they were usually allowed to stir

**Table 1.** Substituted 2-arylbenzimidazoles



Entry	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	Yield (%)	Mp (°C)	Lit. Mp (°C) [ref]
1	H	H	OMe	H	83	224–227	226 <sup>[29]</sup>
2	OMe	H	H	H	60	165–168	171.7–173.9 <sup>[30]</sup>
3	H	OMe	OMe	H	83	216–219	227–228 <sup>[16]</sup>
4	SMe	H	H	H	61	222–224	—
5	Me	H	H	H	79	220–222	221 <sup>[31]</sup>
6	H	Cl	H	H	61	229–231	235–239 <sup>[12]</sup>
7	Cl	H	Cl	H	68	224–226	227–228.5 <sup>[32]</sup>
8	Cl	H	H	Cl	63	> 290	—
9	H	CF <sub>3</sub>	H	H	85	208–210	—
10	H	H	CF <sub>3</sub>	H	81	267	—
11	H	H	COOMe	H	85	228–231	220–222 <sup>[33]</sup>
12	H	H	SO <sub>2</sub> Me	H	70	282	> 300 <sup>[6]</sup>
13	H	NO <sub>2</sub>	H	H	76	203–206	203–205 <sup>[16]</sup>
14	CN	H	H	H	59	248–250	—

overnight. Reactions with benzaldehydes containing electron-withdrawing groups generally required 18 h for completion, although two analogs, *p*-CF<sub>3</sub> and *p*-SO<sub>2</sub>Me (entries 10 and 12), took 72 h and the *o*-CN analog (entry 14) was particularly sluggish, taking 6 days for complete conversion. Performing the reaction under an oxygen atmosphere increases the rate of oxidation somewhat. For example, parallel reactions were carried out on the *m*-CF<sub>3</sub> analog (entry 9), one in air and one under oxygen. After 9 h, conversion of the corresponding benzimidazoline **4** to benzimidazole **5** reached 57%, whereas under oxygen 79% conversion was observed. In either case, complete conversion was achieved after 18 h.

In conclusion, it has been demonstrated that air and NHPI/Co(OAc)<sub>2</sub> is a viable catalytic oxidative system for the conversion of benzimidazolines to benzimidazoles in the reaction of 1,2-phenylenediamine with benzaldehydes.

## EXPERIMENTAL

Melting points were determined on a Thomas-Hoover Uni-melt or Büchi B-545 melting-point apparatus and are uncorrected. All <sup>1</sup>H NMR spectra were recorded on a Bruker 400 Ultrashield instrument, and chemical shifts are relative to internal Me<sub>4</sub>Si.

### General Procedure for the Preparation of Benzimidazoles

A solution of 216 mg (2 mmol) of **1** and 2 mmol of the appropriate aldehyde in 6 mL of MeCN was stirred at room temperature for 15 min, and then 32 mg (0.2 mmol) of NHPI and 2 mg of Co(OAc)<sub>2</sub> were added. The mixture became dark brown and was stirred at room temperature for 18 h. Water was added, and the mixture was extracted with EtOAc. The organic phase was washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure furnished the crude product, which was purified either by trituration with methylene chloride or by silica-gel chromatography using 10% EtOAc/methylene chloride as eluent.

### Spectral Data for Compounds in Table 1

Entry 1: <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 12.74 (s, 1H), 8.12 (d, *J* = 8.97 Hz, 2H), 7.56 (s, broad, 2H), 7.17 (m, 2H), 7.11 (d, *J* = 8.97 Hz, 2H), 3.84 (s, 3H).

Entry 2: <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 12.12 (s, 1H), 8.32 (d, *J* = 9.6 Hz, 1H), 7.65–7.60 (m, 2H), 7.48 (t, 1H), 7.25 (d, *J* = 8.08 Hz, 1H), 7.19 (m, 2H), 7.12 (t, 1H), 4.03 (s, 3H).

Entry 3:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  12.76 (s, broad, 1H), 7.78–7.73 (m, 2H), 7.57 (s, broad, 2H), 7.20–7.15 (m, 2H), 7.13 (d,  $J=8.34$  Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H).

Entry 4:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  12.69 (s, 1H), 7.74 (d,  $J=6.44$  Hz, 1H), 7.68 (d,  $J=7.71$  Hz, 1H), 7.53–7.44 (m, 3H), 7.31 (t, 1H), 7.26–7.18 (m, 2H), 2.43 (s, 3H).

Entry 5:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  12.62 (s, 1H), 7.74 (d,  $J=7.20$  Hz, 1H), 7.68 (d,  $J=7.58$  Hz, 1H), 7.52 (d,  $J=7.45$  Hz, 1H), 7.43–7.34 (m, 3H), 7.25–7.17 (m, 2H), 2.61 (s, 3H).

Entry 6:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.05 (s, 1H), 8.23 (s, 1H), 8.15 (d,  $J=7.07$  Hz, 1H), 7.69 (d,  $J=7.45$  Hz, 1H), 7.62–7.54 (m, 3H), 7.23 (m, 2H).

Entry 7:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  12.78 (s, 1H), 7.94 (d,  $J=8.46$  Hz, 1H), 7.86 (s, 1H), 7.71 (d,  $J=7.58$  Hz, 1H), 7.63 (d,  $J=10.61$  Hz, 1H), 7.58 (d,  $J=7.58$  Hz, 1H), 7.25 (m, 2H).

Entry 8:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  12.85 (s, 1H), 7.72–7.59 (m, 4H), 7.55 (d,  $J=8.34$  Hz, 1H), 7.25 (m, 2H).

Entry 9:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.18 (s, 1H), 8.53 (s, 1H), 8.49 (d,  $J=7.83$  Hz, 1H), 7.88–7.79 (m, 2H), 7.71 (d,  $J=7.71$  Hz, 1H), 7.58 (d,  $J=7.58$  Hz, 1H), 7.25 (m, 2H).

Entry 10:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.19 (s, 1H), 8.39 (d,  $J=8.08$  Hz, 2H), 7.94 (d,  $J=8.21$  Hz, 2H), 7.72 (d,  $J=7.71$  Hz, 1H), 7.58 (d,  $J=7.33$  Hz, 1H), 7.25 (m, 2H).

Entry 11:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.15 (s, 1H), 8.32 (d,  $J=8.34$  Hz, 2H), 8.13 (d,  $J=8.46$  Hz, 2H), 7.71 (d,  $J=7.58$  Hz, 1H), 7.57 (d,  $J=7.74$  Hz, 1H), 7.25 (m, 2H).

Entry 12:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.22 (s, 1H), 8.42 (d,  $J=8.46$  Hz, 2H), 8.11 (d,  $J=8.46$  Hz, 2H), 7.72 (d,  $J=7.83$  Hz, 1H), 7.58 (d,  $J=7.71$  Hz, 1H), 7.26 (m, 2H), 3.30 (s, 3H).

Entry 13:  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.31 (s, 1H), 9.02 (s, 1H), 8.62 (d,  $J=7.83$  Hz, 1H), 8.34 (d,  $J=6.82$  Hz, 1H), 7.87 (t, 1H), 7.73 (d, broad,  $J=7.58$  Hz, 1H), 7.59 (d, broad,  $J=7.45$  Hz, 1H), 7.26 (m, 2H).

Entry 14: IR (ATR mode):  $2226\text{ cm}^{-1}$ ;  $^1\text{H}$ -NMR ( $\text{DMSO-d}_6$ ):  $\delta$  13.11 (s, 1H), 8.09 (d,  $J=8.59$  Hz, 1H), 8.04 (d,  $J=6.82$  Hz, 1H), 7.90 (t, 1H), 7.76–7.68 (m, 2H), 7.60 (d,  $J=7.71$  Hz, 1H), 7.28 (m, 2H).

## REFERENCES

1. Roth, T.; Morningstar, M. L.; Boyer, P. L.; Hughes, S. H.; Buckheit, Jr., R. W.; Michejda, C. J. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase: 2-Aryl-substituted benzimidazoles. *J. Med. Chem.* **1997**, *40*, 4199–4207.

2. Leonard, J. T.; Jeyaseeli, L.; Rajesh, O. S.; Muruges, K.; Sivakumar, R.; Gunasekaran, V. Synthesis, anti-inflammatory and antibacterial activities of 4-substituted phenyl benzimidazoles. *Asian J. Chem.* **2006**, *18*, 1104–1108.
3. Sondhi, S. M.; Singh, N.; Kumar, A.; Lozach, O.; Meijer, L. Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. *Bioorg. Med. Chem.* **2006**, *14*, 3758–3765.
4. Lee-Dutra, A.; Arienti, K. L.; Buzard, D. L.; Hack, M. D.; Khatuya, H.; Desai, P. J.; Nguyen, S.; Thurmond, R. L.; Karlsson, L.; Edwards, J. P.; Breitenbucher, J. G. Identification of 2-arylbenzimidazoles as potent human histamine H<sub>4</sub> receptor ligands. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 6043–6048.
5. White, A. W.; Curtin, N. J.; Eastman, B. W.; Golding, B. T.; Hostomsky, Z.; Kyle, S.; Li, J.; Maegley, K. A.; Skalizky, D. J.; Webber, S. E.; Yu, X.-H.; Griffin, R. J. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2433–2437.
6. Rose, U. 2-Arylsubstituierte benzoanellierte 5-ring-heterocyclen als potentielle wirkstoffe im kardiovaskulären system. *Pharmazie*. **1991**, *46*, 775–777.
7. Güngör, T.; Fouquet, A.; Teulon, J.-M.; Provost, D.; Cazes, M.; Cloarec, A. Cardiotonic agents: Synthesis and cardiovascular properties of novel 2-arylbenzimidazoles and azabenzimidazoles. *J. Med. Chem.* **1992**, *35*, 4455–4463; (b) Mertens, A.; Müller-Beckmann, B.; Kampe, W.; Hölk, J.-P.; von der Saal, W. Nonsteroidal cardiotonics, 1: 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents. *J. Med. Chem.* **1987**, *30*, 1279–1287.
8. (a) Dunwell, D. W.; Evans, D.; Smith, C. E.; Williamson, W. R. N. Synthesis and antiinflammatory activity of some 2-substituted  $\alpha$ -methyl-5-benzimidazoleacetic acids. *J. Med. Chem.* **1975**, *18*, 692–694; (b) Dzvinchuk, I. B.; Vypirailenko, A. V.; Lozinskii, M. O. Synthesis of 1-(5-pyrazolyl)benzimidazoles by cyclocondensation of 5-[(o-acylaminophenyl)amino]pyrazoles. *Russian. J. Org. Chem.* **1998**, *34*, 685–687.
9. (a) Gong, B.; Hong, F.; Kohm, C.; Bonham, L.; Klein, P. Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase- $\beta$ . *Bioor. Med. Chem. Lett.* **2004**, *14*, 1455–1459; (b) Huang, S.-T.; Hsei, I.-J.; Chen, C. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles. *Bioor. Med. Chem.* **2006**, *14*, 6106–6119.
10. Kumar, D.; Jacob, M. R.; Reynolds, M. B.; Kerwin, S. M. Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. *Bioor. Med. Chem.* **2002**, *10*, 3997–4004.
11. Charles, E. S.; Rao, K. V. B.; Sharma, S. Synthesis of substituted benzamides and benzimidazoles as anthelmintic and antimicrobial agents. *Pharmazie* **1982**, *37*, 423–415.



12. Heravi, M. M.; Tajbakhsh, M.; Ahmadi, A. N.; Mohajerani, B. Zeolites. Efficient and eco-friendly catalysts for the synthesis of benzimidazoles. *Monatsh. Chem.* **2006**, *137*, 175–179.
13. Biasotti, B.; Dallavalle, S.; Merlini, L.; Farina, C.; Gagliardi, S.; Parini, C.; Belfiore, P. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase. *Bioor. Med. Chem.* **2003**, *11*, 2247–2254.
14. Stephens, F. F.; Bower, J. D. Preparation of benzimidazoles and benzoxazoles from Schiff bases. *J. Chem. Soc.* **1949**, 2971–2972.
15. Singh, M. P.; Sasmal, S.; Lu, W.; Chatterjee, M. N. Synthetic utility of catalytic Fe(III)/Fe(II) redox cycling towards fused heterocycles: A facile access to substituted benzimidazole, bis-benzimidazole and imidazopyridine derivatives. *Synthesis* **2000**, 1380–1390.
16. Chakrabarty, M.; Karmakar, S.; Mukherji, A.; Arima, S.; Harigaya, Y. Application of sulfamic acid as an eco-friendly catalyst in an expedient synthesis of benzimidazoles. *Heterocycles* **2006**, *68*, 967–974.
17. Curini, M.; Epifano, F.; Montanari, F.; Rosati, O.; Taccone, S. Ytterbium triflate promoted synthesis of benzimidazole derivatives. *Synlett.* **2004**, 1832–1834.
18. Nagata, K.; Itoh, T.; Ishikawa, H.; Ohsawa, A. Synthesis of 2-substituted benzimidazoles by reaction of o-phenylenediamine with aldehydes in the presence of Sc(OTf)<sub>3</sub>. *Heterocycles* **2003**, *61*, 93–96.
19. Beaulieu, P. L.; Haché, B.; von Moos, E. A practical oxone-mediated, high-throughput, solution-phase synthesis of benzimidazoles from 1,2-phenylenediamines and aldehydes and its application to preparative scale synthesis. *Synthesis* **2003**, 1683–1692.
20. Bahrami, K.; Khodaei, M. M.; Kaviani, I. A simple and efficient one-pot synthesis of 2-substituted benzimidazoles. *Synthesis* **2007**, 547–550.
21. Ma, H.; Wang, Y.; Wang, J. A simple KHSO<sub>4</sub>-promoted synthesis of 2-aryl-substituted benzimidazoles by oxidative condensation of aldehydes with o-phenylenediamine. *Heterocycles* **2006**, *68*, 1669–1673.
22. Ishii, Y.; Nakayama, K.; Takeno, M.; Sakaguchi, S.; Iwahama, T.; Nishiyama, Y. A novel catalysis of N-hydroxyphthalimide in the oxidation of organic substrates by molecular oxygen. *J. Org. Chem.* **1995**, *60*, 3934–3935.
23. Iwahama, T.; Sakaguchi, S.; Nishiyama, Y.; Ishii, Y. Aerobic oxidation of alcohols to carbonyl compounds catalyzed by N-hydroxyphthalimide (NHPI) combined with Co(acac)<sub>3</sub>. *Tetrahedron Lett.* **1995**, *36*, 6923–6926.
24. Ishii, Y.; Iwahama, T.; Sakaguchi, S.; Nakayama, K.; Nishiyama, Y. Alkane oxidation with molecular oxygen using a new efficient catalytic system: N-hydroxyphthalimide (NHPI) combined with Co(acac)<sub>n</sub> (n = 2 or 3). *J. Org. Chem.* **1996**, *61*, 4520–4526.
25. Yoshino, Y.; Hayashi, Y.; Iwahama, T.; Sakaguchi, S.; Ishii, Y. Catalytic oxidation of alkylbenzenes with molecular oxygen under normal pressure and temperature by N-hydroxyphthalimide combined with Co(OAc)<sub>2</sub>. *J. Org. Chem.* **1997**, *62*, 6810–6813.
26. Han, B.; Liu, Q.; Liu, Z.; Mu, R.; Zhang, W.; Liu, Z.-L.; Yu, W. A metal-free catalytic aerobic aromatization of Hantzsch 1,4-dihydropyridines by N-hydroxyphthalimide. *Synlett* **2005**, *15*, 2333–2334.

27. Han, B.; Liu, Z.; Liu, Q.; Yang, L.; Liu, Z.-L.; Yu, W. An efficient aerobic oxidative aromatization of Hantzsch 1,4-dihydropyridines and 1,3,5-trisubstituted pyrazolines. *Tetrahedron* **2006**, *62*, 2492–2496.
28. Lin, S.; Yang, L. A simple and efficient procedure for the synthesis of benzimidazoles using air as the oxidant. *Tetrahedron Lett.* **2005**, *46*, 4315–4319.
29. Alloum, A. B.; Bougrin, K.; Soufiaoui, M. Synthèse chimiosélective des benzimidazoles sur silice traitée par le chlorure du thionyle. *Tetrahedron Lett.* **2003**, *44*, 5935–5937.
30. Navarrete-Vázquez, G.; Moreno-Díaz, H.; Aguirre-Crespo, F.; León-Rivera, I.; Villalobos-Molina, R.; Muñoz-Muñiz, O.; Estrada-Soto, S. Design, microwave-assisted synthesis, and spasmolytic activity of 2-(alkyloxyaryl)-1H-benzimidazole derivatives as constarined stilbene bioisosteres. *Bioor. Med. Chem. Lett.* **2006**, *16*, 4169–4173.
31. Nardi, D.; Tajana, A.; Rossi, S. Heterocyclic compounds from 3,3-dimercapto-1-aryl-2-propen-1-ones, note 1: 4-Aryl-1,3-dihydro-2H-1,5-benzodiazepine-2-thiones. *J. Heterocyc. Chem.* **1973**, *10*, 815–819.
32. Zaika, L.; Joullié, M. M. 1,2,3-Benzotriazines, II: Reactions of benzimidazo[1,2-c]benzotriazines and naphth[1',2'(2',1'):4,5]imidazo[1,2-c][1,2,3]benzotriazine. *J. Heterocyc. Chem.* **1966**, *3*, 444–449.
33. Perry, R. J.; Wilson, B. D. A novel palladium-catalyzed synthesis of 2-arylbenzimidazoles. *J. Org. Chem.* **1993**, *58*, 7016–7021.